CD274 and neoplasm: The KEYNOTE-024 study compared pembrolizumab monotherapy (PM) versus chemotherapy in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or greater.